

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 28-03-2007

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 20-1-2007 TO BE PUBLISHED ON 28-3-2007 IN  
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

|         |  |  |
|---------|--|--|
| 37/2007 | <b><u>15-01-2007</u></b><br>Eli Lilly and company.<br>USA.<br>(Priority 24-01-2006 US)   | “Indole sulfonamide modulators of progesterone receptors”  |
| 38/2007 | E.I. DU Pont DE Nemours and Company.<br>USA.<br>(Priority 27-01-2006 US)                 | “Fluoroalkenyl derivatives as insecticides and nematocides”  |
| 39/2007 | <b><u>16-01-2007</u></b><br>AstraZeneca AB.<br>Sweden.<br>(Priority 26-01-2006 US)       | “Pyrimidine derivatives”   |
| 40/2007 | Nestec S.A.<br>Switzerland.<br>(Priority 02-02-2006 EP)                                  | “Improvement of cold liquid solubility of fat-containing powders”  |
| 41/2007 | GCG Holdings Ltd.<br>Bahamas.<br>(Priority 17-01-2006 USA)                               | “Stud with lengthwise indented ribs and method”  |
| 42/2007 | Honda Motor Co. Ltd.<br>Japan.<br>(Priority 20-01-2006 Japan)                            | “Decompression device of internal combustion engine”   |
| 43/2007 | <b><u>17-01-2007</u></b><br>AstraZeneca AB.<br>Sweden.<br>(Priority 02-02-2006 USA)      | “A new salt”   |
| 44/2007 | AstraZeneca AB.<br>Sweden.<br>(Priority 27-06-2006 USA)                                  | “Novel heteroaryl substituted benzothiazoles”  |
| 45/2007 | Bows Pharmaceuticals AG.<br>Switzerland.<br>(Priority 18-01-2006 Sweden)                 | “Methods and compositions”   |
| 46/2007 | Athersys, Inc.<br>USA.<br>(Priority 19-01-2006 USA)                                      | “Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof”   |
| 47/2007 | <b><u>18-01-2007</u></b><br>Quark Biotech, Inc.<br>Germany.<br>(Priority 20-01-2006 USA) | “Therapeutic uses of inhibitors of RTP801”   |
| 48/2007 | Bayer HealthCare AG.<br>Germany.<br>(Priority 24-12-1999 Germany)                        | “A substituted oxazolidinone, process for its preparation and a pharmaceutical composition comprising thereof for the prophylaxis and/or |

|         |  |  |
|---------|--|--|
|         | <b>Divisional.</b>   | treatment of disorders”  |
| 49/2007 | Honda Motor Co. Ltd.<br>Japan.<br>(Priority 27-02-2006 Japan)  | “Clutch release mechanism”   |
| 50/2007 | Technology Incubation Centre,(Nust).<br>Pakistan.  | “D-I-S-D device for speech impaired and deaf”  |
|         | <b><u>20-01-2007</u></b>   |  |
| 01/2007 | Mr. Imtiaz Rastgar.<br>VC/CEO Engineering Development<br>Board. (NUST)<br>Pakistan.  | “ECO-GIN”  |
| 51/2007 | 1.Zahida N. Umar.<br>2.Muhammad Kamran.<br>3.Nida Saleem.<br>Pakistran.  | “Ready to eat (RTE) wheat based breakfast with<br>fruit”   |
| 52/2007 | Novartis AG.<br>Switzerland.<br>(Priority 20-01-2006 US)   | “P1-3 kinase inhibitors and methods of their use”  |
| 53/2007 | Syngenta Limited.<br>United Kingdom.<br>(Priority 23-01-2006 UK)   | “Herbicidal formulation”   |
| 54/2007 | 1.Idenix (Cayman) Limited<br>Islands<br>2. Universita Degli Studi DI Caglairi.<br>Italy.<br>(Priority 28-06-2002 US)<br><b>Divisional.</b> | “2’-C-methyl-3’-O-L-valine ester ribofuranosyl<br>cytidine for treatment of flaviviridae infections”   |
| 55/2007 | Honda Motor Co. Ltd.<br>Japan.<br>(Priority 06-03-2006 Japan)  | “Exhaust emission control device for engine”   |
| 56/2007 | Merz Pharma GMBH & Co. KGAA.<br>Germany.<br>(Priority 21-03-2002 US)<br><b>Divisional.</b>   | “An optical isomer and a<br>pharmaceutically-acceptable acid or base addition<br>salt of an azabicyclic, azatricyclic and<br>azaspirocyclic derivatives of aminocyclohexane<br>nmda 5HT3, and neuronal nicotinic receptor<br>antaginsts” |
| 57/2007 | Novartis AG.<br>Switzerland.<br>(Priority 23-01-2006 USA)  | “Organic compounds”  |

#### APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this

Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

|          |  |  |
|----------|--|--|
| 227/1999 | 1. BASF<br>Aktiengesellschaft,<br>Germany<br>2. BASF Corporation,<br>USA | “Plant growth regulator composition comprising a mepiquat borate compound”<br><br>(Class: A01N, 59/14) |
|----------|--|--|

139228

Comprises relates to mepiquat borate compound, to its use as plant growth regulator.

|          |                                  |  |
|----------|----------------------------------|--|
| 218/2002 | Bristol-Myers Squibb Co.,<br>USA | “A pharmaceutical composition suitable for oral administration comprising aripiprazole”<br><br>(Class: A61K, 31/495) |
|----------|----------------------------------|--|

139229

Comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste enhancing/masking agent and one or more agents selected from the group consisting of lactic acid, acetic acid, wherein said solution has a PH from 2.5 – 4.5.

270/2005 Dr. Shah Alam Khan,  
Mahtab Faisal,  
Mushtaq-ur-Rahman,  
PCSIR, Peshawar,  
Pakistan

“A process for the production of high performance cement based on mineral additives”

(Class: C04B, 7/12)

139230

Comprises calcinations of the indigenous pozzolana at a temperature of 850-950°C, subjecting the calcined material to lime reactivity tests after fine grinding to mesh size of - 200, blending the Portland cement with the calcined material, moulding of 2” x 2” cubes from the cement/pozzolana mixture and finally curing the cubes in water.

271/2005 Dr. Shah Alam Khan,  
Mahtab Faisal,  
Mushtaq-ur-Rahman,  
PCSIR, Peshawar,  
Pakistan

“A process for the production of a composition for preparing acid resistant cement”

(Class: C04B, 7/13)

139231

Comprising adding liquid sodium silicate to a mixture of silica sand, asbestos and lead oxide, casting the mix into cubes and drying the cubes at 60-100°C to attain maximum strength.

272/2005 Dr. Shah Alam Khan,  
Mahtab Faisal,  
Mushtaq-ur-Rahman,  
PCSIR, Peshawar,

“A process of hydrothermal treatment of mineral aggregates for the production of cementitious product”

Pakistan

(Class: C04B, 7/13)

139232

Comprises mixing of hydrated lime, silica sand and china clay, moulding of the mixture at a steam pressure of 30.7MPa after adding the requisite amount of water and then autoclaving the specimens for a period of 6, 12, 18, 22 & 48 hours at a steam pressure of 0.1MPa (100°C).

330/2005 Dr. Shah Alam Khan,  
Mahtab Faisal,  
Mushtaq-ur-Rahman,  
PCSIR, Peshawar,  
Pakistan

“A process for the production of epoxy resin based cement mortar”

(Class: C04B, 16/20)

139233

Comprises mixing of resin, hardener and filling material, casting the mixture into cubes, and drying the cubes at 20-30°C for 9 days to attain full mechanical strength.

### **SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139224

Merck Frosst Canada & Co.  
Canada

228/2001

139225

Bayer CropScience S.A.,  
Freance.

973/2002

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Tel: 9215488